The Rivkin Center Has Joined OCRA
The Rivkin Center Has Joined OCRA
This historic collaboration unites two respected organizations committed to advancing research for better treatments and a cure for ovarian cancer.
Expanding Research Through Partnership
Ovarian Cancer Research Alliance (OCRA), the world’s leading ovarian and gynecologic cancer nonprofit, is proud to announce that the Rivkin Center for Ovarian Cancer Research has combined with OCRA.
Please explore the resources below to learn more about the support and tools available from OCRA.
Support The Rivkin Pilot Grant
The Rivkin Pilot Grant paves the way for innovative breakthroughs in all areas of ovarian cancer research. OCRA is proud to continue the Rivkin Center’s extraordinary legacy of hope, determination, and relentless pursuit of a cure.
Support & Resources
Research
Advocacy
Get Involved
OCRA Rivkin Family SummeRun
On July 13, 2025, join thousands of participants of all ages and fitness levels at Seattle’s Seward Park to raise awareness and fund critical research for ovarian cancer. Funds raised will support The Rivkin Pilot Grant. Registration opens in early April.
About
Related Topics
OCRA Invests More than $10.8 Million Toward Research, Part of $14.5 Million Commitment in 2025
In 2025, Ovarian Cancer Research Alliance (OCRA) invested more than $10.8 million toward scientific research—part of our $14.5 million commitment to strengthen the community through research, patient support, education and advocacy. This year’s investment represents OCRA’s broadest scope to date, encompassing not only our renowned grant programs but also global collaborations leveraging artificial intelligence (AI) … Continued
The Overview: October 2025
KVIA-TV ABC-7 News El Paso recently featured OCRA-funded researcher Daniel Heller, PhD, and his team at Memorial Sloan Kettering Cancer Center, whose innovative work is bringing new hope for detecting ovarian cancer at its earliest stages through a simple blood test. Dr. Heller’s research lab is developing a liquid biopsy that uses nanosensors and artificial intelligence (AI) to measure multiple proteins … Continued
OCRA Sponsors NCCN 2025 Guidelines for Cervical, Ovarian, and Uterine Cancer Patients
This article was updated in October 2025 to reflect NCCN’s release of the 2025 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2025 Patient Guidelines for Cervical, Ovarian, and Uterine Cancer. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful guides for anyone newly diagnosed to help … Continued